USFDA ANDA Approvals: Weekly Regulatory Intelligence Update – 03 to 10 September 2026

INTELLIGENCE BRIEFThe U.S. Food and Drug Administration (USFDA) granted multiple Abbreviated New Drug Application (ANDA) approvals between 03 and 10 September 2026, covering therapeutic areas including oncology, anticonvulsants, cardiovascular diseases,…

Continue ReadingUSFDA ANDA Approvals: Weekly Regulatory Intelligence Update – 03 to 10 September 2026

FDA Publishes Draft Guidance on Compounding Animal Drugs from Bulk Drug Substances

FDA Publishes Draft Guidance on Compounding Animal Drugs from Bulk Drug Substances Authority: U.S. Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM)Document: Draft Guidance for Industry GFI #256BDate:…

Continue ReadingFDA Publishes Draft Guidance on Compounding Animal Drugs from Bulk Drug Substances

USFDA ANDA Approvals Analysis: Tracking the Specialty and Generic Landscape (June 09 – 13, 2026)

The global pharmaceutical landscape is shifting rapidly, driven by strategic generic entries and a clear push toward high-barrier formulations. An analysis of the Abbreviated New Drug Application (ANDA) approvals from…

Continue ReadingUSFDA ANDA Approvals Analysis: Tracking the Specialty and Generic Landscape (June 09 – 13, 2026)

USFDA ANDA Approvals Analysis: Tracking the Specialty and Generic Landscape (June 01 – 06, 2026)

The U.S. Food and Drug Administration (USFDA) continued its steady pace of generic drug approvals during the first week of June 2026, granting multiple Abbreviated New Drug Application (ANDA) approvals…

Continue ReadingUSFDA ANDA Approvals Analysis: Tracking the Specialty and Generic Landscape (June 01 – 06, 2026)

Rubicon Research Limited Receives USFDA Approval for Clonazepam Tablets

On 21-May2026, Rubicon Research Limited has received approval from the U.S. Food and Drug Administration (USFDA) for its Clonazepam Tablets USP through the Abbreviated New Drug Application (ANDA) pathway under…

Continue ReadingRubicon Research Limited Receives USFDA Approval for Clonazepam Tablets

Bhutan BFDA Draft Guideline 2026: Strengthening Medical Product Import Controls

Date of Publication: 22-May-2026 INTELLIGENCE OVERVIEWAgency: Bhutan FDAThe Bhutan Food and Drug Authority (BFDA) has released a draft guideline on the Importation, Consignment Verification, and Lot Release of Medical Products…

Continue ReadingBhutan BFDA Draft Guideline 2026: Strengthening Medical Product Import Controls

USFDA ANDA Approvals Analysis: Tracking the Specialty and Generic Landscape (May 15–20, 2026)

In the pharmaceutical industry, staying ahead of regulatory updates is a baseline requirement; translating those updates into actionable market intelligence is what drives strategic advantage.Over a brief six-day period mid-month,…

Continue ReadingUSFDA ANDA Approvals Analysis: Tracking the Specialty and Generic Landscape (May 15–20, 2026)

FDA Adopts ICH M11 Guidance for Clinical Electronic Structured Harmonized Protocol (CeSHarP)

Date of Publication: 20-May-2026 INTELLIGENCE OVERVIEWAgency: USFDAThe FDA has released the ICH M11 Clinical Electronic Structured Harmonized Protocol (CeSHarP) Guidance for Industry, introducing a standardized approach for structuring and electronically…

Continue ReadingFDA Adopts ICH M11 Guidance for Clinical Electronic Structured Harmonized Protocol (CeSHarP)